 SAN DIEGO, Aug. 25, 2022 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. NASDAQ: TVTX today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Companys ongoing longitudinal natural history study of people living with classical homocystinuria HCU, at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU. 